From Our Thought Leaders

AAVantgarde Advances Dual-AAV Gene Therapies for Usher Syndrome and Stargardt Disease

Inherited retinal diseases such as Usher syndrome and Stargardt disease remain difficult to treat, particularly when the genes involved are too large for conventional gene therapy delivery systems. AAVantgarde is advancing its dual-AAV platform throu... Read more

17 November, 2026 | Tuesday | Interaction
Quotient Sciences Advances AI-Guided Drug Formulation to Shorten Clinical Development

Developing effective drug formulations remains a major challenge for biopharma companies, particularly for molecules with poor solubility or complex release requirements. Quotient Sciences is exploring how machine learning and integrated manufacturin... Read more

16 November, 2026 | Monday | Interaction
MRM Health and Biocodex Advance €15 Million Manufacturing Partnership for Microbiome-Based Medicines

Bringing microbiome-based therapies to patients requires more than promising clinical results. Manufacturing complex mixtures of live bacteria consistently and at commercial scale remains a major challenge. MRM Health is addressing this through its p... Read more

13 November, 2026 | Friday | Interaction
Pharvaris Reports Positive Phase 3 Results for Oral Deucrictibant in Hereditary Angioedema

For people living with hereditary angioedema (HAE), sudden and unpredictable swelling attacks can disrupt daily life and require urgent treatment. Pharvaris is developing deucrictibant, an investigational oral therapy designed to provide rapid reli... Read more

12 November, 2026 | Thursday | News

Bio Finance

Bavarian Nordic Launches Second DKK 250 Million Share Buyback Tranche Under DKK 750 Million Programme

Bavarian Nordic A/S (OMX: BAVA) launches the second tranche of the share buy-back program announced on August 21, under which the Company intends to repurchase own shares for up to DKK 750 million. The second tranche will comprise buy-back of shares ... Read more

16 November, 2026 | Monday | News
ArrayPatch Raises €3.2 Million in Seed Funding to Advance Microneedle Patch Treatments for Obesity and Cancer

ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, announced the successful completion of the second close of its seed financing round, securing an additional €1.6 million, bringing... Read more

06 November, 2026 | Friday | News

Contract Services

Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib for Moderate-to-Severe Lichen Planus

Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options - Unique Mechanism Targets Key Pathwa... Read more

17 November, 2026 | Tuesday | News
Eisai and Biogen Launch LEQEMBI Pen in Japan for Once-Weekly Alzheimer's Disease Treatment

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of “LEQEMBI®” (generic name: lecanemab) has been launched in Japan. LEQEMBI Pen was approved as a new rou... Read more

16 November, 2026 | Monday | News

BioPharma Video

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close